Submitted by Anonymous (not verified) on 30 October 2023 - 10:59
Human medicines European public assessment report (EPAR): Adtralza, tralokinumab, Dermatitis, Atopic, Date of authorisation: 17/06/2021, Revision: 4, Status: Authorised
Source: